The Phase 3 EPIC trial is a randomized, sham-controlled, double-blind study evaluating NRTX-1001 cell therapy in adults with ...

Michigan Medicine researchers have developed a SCN1B gene therapy that restores brain function and survival in mice with ...

Biogen and Stoke Therapeutics have signed a deal to co-develop and sell Stoke’s experimental drug for Dravet syndrome, ...

Recent research takes aim at the a variant in gene SCN1B, which causes a severe form of developmental epileptic encephalopathy.

The Phase 3 EPIC trial is a randomized, sham-controlled, double-blind study evaluating NRTX-1001 cell therapy in adults with drug-resistant mesial temporal lobe epilepsy SAN FRANCISCO, Feb.

A new treatment option has become available for severe epilepsy: fenfluramine, which is now available on the NHS ...

Epilepsy in children can be a challenging condition to manage. Here's a comprehensive overview of the causes, dietary ...

Administering the therapy to newborn mice increased their survival, reduced the severity of their seizures and restored brain neuron excitability. The team notes that different forms of SCN1B gene ...

In the evolving landscape of medical advancements, focused ultrasound has emerged as a groundbreaking, non-invasive therapy ...